Thiamidol containing treatment regimens in facial hyperpigmentation: An international multi‐centre approach consisting of a double‐blind, controlled, split‐face study and of an open‐label, real‐world study

OBJECTIVE: Tyrosinase is the rate‐limiting enzyme in melanogenesis. Thiamidol is the most potent inhibitor of human tyrosinase out of 50 000 tested compounds. In clinical studies, it was shown to improve facial hyperpigmentation, post‐inflammatory hyperpigmentation and age spots significantly. To id...

Descripción completa

Detalles Bibliográficos
Autores principales: Philipp‐Dormston, W. G., Vila Echagüe, A., Pérez Damonte, S. H., Riedel, J., Filbry, A., Warnke, K., Lofrano, C., Roggenkamp, D., Nippel, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576892/
https://www.ncbi.nlm.nih.gov/pubmed/32390164
http://dx.doi.org/10.1111/ics.12626

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576892/
https://www.ncbi.nlm.nih.gov/pubmed/32390164
http://dx.doi.org/10.1111/ics.12626

Ejemplares similares